Looking to sell Viz.ai stock or options?
Viz.ai, a developer of a smart care coordination platform, is dedicated to revolutionizing global healthcare delivery. The company's platform harnesses the power of advanced deep learning to relay critical information about stroke patients directly to a specialist who can provide immediate treatment. This enables healthcare providers to decrease treatment times and enhance patient access to care.
Camford Capital, Susa Ventures, Greenoaks Capital Partners, AME Cloud Ventures, Seedcamp, Kevin Ding, Threshold Ventures, Jukka Jokinen, Halle Tecco, Scale Venture Partners, GV, CRV, Pear (California), DHVC, Geodesic Capital, Tiger Global Management, J Mocco, Canadian Imperial Bank of Commerce, Hakluyt Capital, Innovation Endeavors, Sozo Ventures.
Viz.ai is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Viz.ai stock. Depending on Viz.ai’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Viz.ai stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Viz.ai stock in two ways. First, Viz.ai employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Viz.ai stock. Note that all transactions in Viz.ai shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Viz.ai stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Viz.ai stock. Typically, shares of private companies like Viz.ai are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Mar 2023, Viz.ai is reported to have closed an equity financing in which the investors valued the company at $0. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Viz.ai shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Viz.ai is not currently publicly traded, it does not have a ticker symbol.
Viz.ai has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Viz.ai is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Viz.ai shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
SAN FRANCISCO - Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced Chris Mansi, MD, CEO and Co-founder, will present at the Morgan Stanley 22nd...
Collaboration aims to help cryptogenic stroke patients receive necessary cardiology follow-up to reduce risk of secondary strokeSAN FRANCISCO--(BUSINESS
New AI algorithm enables precise and reliable quantification of intracerebral hemorrhage to make accurate and timely treatment decisionsSAN
The AI-powered diagnostic platform can diagnose the presence of aneurysms by analysing computed tomography (CT) scans.
The startup has 12 FDA-approved algorithms, agreements with more than 1,500 U.S. hospitals, and plans to work with drug companies to reduce healthcare roadblocks.
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of VizTM Vascular Suite, AI-powered software enabling vascular care teams to automatically detect and triage…
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has received two additional Comparably Best Place to Work Awards for Best Company Culture and Best Company for Diversity in 2022. Earli…
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with Cercare Medical, which delivers next-level medical imaging with CT and MRI. The partnership will inc…
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Radiology Advisory Board to assist Viz.ai in the development of strategy and products to support ra…
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic partnership with Vastrax, the leading full-service, vascular clinical research organization (CRO). Together…